BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 33788262)

  • 1. Relationships between highly recurrent tumor suppressor alterations in 489 leiomyosarcomas.
    Schaefer IM; Lundberg MZ; Demicco EG; Przybyl J; Matusiak M; Chibon F; Ingram DR; Hornick JL; Wang WL; Bauer S; Baker LH; Lazar AJ; van de Rijn M; Mariño-Enríquez A; Fletcher JA
    Cancer; 2021 Aug; 127(15):2666-2673. PubMed ID: 33788262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular biomarkers for uterine leiomyosarcoma and endometrial stromal sarcoma.
    Tsuyoshi H; Yoshida Y
    Cancer Sci; 2018 Jun; 109(6):1743-1752. PubMed ID: 29660202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HPV51-associated Leiomyosarcoma: A Novel Class of TP53/RB1-Wildtype Tumor With Predilection for the Female Lower Reproductive Tract.
    Williams EA; Montesion M; Lincoln V; Tse JY; Hiemenz MC; Mata DA; Shah BB; Shoroye A; Alexander BM; Werth AJ; Foley-Peres K; Milante RR; Ross JS; Ramkissoon SH; Williams KJ; Adhikari LJ; Zuna RE; LeBoit PE; Lin DI; Elvin JA
    Am J Surg Pathol; 2022 Jun; 46(6):729-741. PubMed ID: 35034043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atypical Uterine Smooth Muscle Tumors: A Retrospective Evaluation of Clinical and Pathologic Features.
    Maltese G; Fontanella C; Lepori S; Scaffa C; Fucà G; Bogani G; Provenzano S; Carcangiu ML; Raspagliesi F; Lorusso D
    Oncology; 2018; 94(1):1-6. PubMed ID: 28869928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma.
    Leitao MM; Soslow RA; Nonaka D; Olshen AB; Aghajanian C; Sabbatini P; Dupont J; Hensley M; Sonoda Y; Barakat RR; Anderson S
    Cancer; 2004 Sep; 101(6):1455-62. PubMed ID: 15316901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular-Based Immunohistochemical Algorithm for Uterine Leiomyosarcoma Diagnosis.
    Momeni-Boroujeni A; Yousefi E; Balakrishnan R; Riviere S; Kertowidjojo E; Hensley ML; Ladanyi M; Ellenson LH; Chiang S
    Mod Pathol; 2023 Apr; 36(4):100084. PubMed ID: 36788080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical Sequencing.
    Hensley ML; Chavan SS; Solit DB; Murali R; Soslow R; Chiang S; Jungbluth AA; Bandlamudi C; Srinivasan P; Tap WD; Rosenbaum E; Taylor BS; Donoghue MTA; Hyman DM
    Clin Cancer Res; 2020 Jul; 26(14):3881-3888. PubMed ID: 32299819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted exome sequencing profiles genetic alterations in leiomyosarcoma.
    Agaram NP; Zhang L; LeLoarer F; Silk T; Sung YS; Scott SN; Kuk D; Qin LX; Berger MF; Antonescu CR; Singer S
    Genes Chromosomes Cancer; 2016 Feb; 55(2):124-30. PubMed ID: 26541895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive immunohistochemical analysis based on the origin of leiomyosarcoma.
    Bayçelebi D; Kefeli M; Yıldız L; Karagöz F
    Pol J Pathol; 2022; 73(3):233-243. PubMed ID: 36734438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case Report: A Low-grade Uterine Leiomyosarcoma Showing Multiple Genetic Aberrations Including a Bi-allelic Loss of the Retinoblastoma Gene Locus, as well as Germ-line Uniparental Disomy for Part of the Long Arm of Chromosome 22.
    Holzmann C; Koczan D; Loening T; Rommel B; Bullerdiek J
    Anticancer Res; 2017 May; 37(5):2233-2237. PubMed ID: 28476787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogen and progesterone receptor expression in uterine and extrauterine leiomyosarcomas: an immunohistochemical study.
    Kelley TW; Borden EC; Goldblum JR
    Appl Immunohistochem Mol Morphol; 2004 Dec; 12(4):338-41. PubMed ID: 15536333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abnormal p53 and p16 staining patterns distinguish uterine leiomyosarcoma from inflammatory myofibroblastic tumour.
    Schaefer IM; Hornick JL; Sholl LM; Quade BJ; Nucci MR; Parra-Herran C
    Histopathology; 2017 Jun; 70(7):1138-1146. PubMed ID: 28130839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the Molecular and Immunologic Features of Leiomyosarcoma.
    Cope BM; Traweek RS; Lazcano R; Keung EZ; Lazar AJ; Roland CL; Nassif EF
    Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inactivation of RB1, CDKN2A, and TP53 have distinct effects on genomic stability at side-by-side comparison in karyotypically normal cells.
    Andersson N; Saba KH; Magnusson L; Nilsson J; Karlsson J; Nord KH; Gisselsson D
    Genes Chromosomes Cancer; 2023 Feb; 62(2):93-100. PubMed ID: 36124964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
    Hamid AA; Gray KP; Shaw G; MacConaill LE; Evan C; Bernard B; Loda M; Corcoran NM; Van Allen EM; Choudhury AD; Sweeney CJ
    Eur Urol; 2019 Jul; 76(1):89-97. PubMed ID: 30553611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The selected biomarker analysis in 5 types of uterine smooth muscle tumors.
    Zhang Q; Kanis MJ; Ubago J; Liu D; Scholtens DM; Strohl AE; Lurain JR; Shahabi S; Kong B; Wei JJ
    Hum Pathol; 2018 Jun; 76():17-27. PubMed ID: 29258902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrated genomic and transcriptomic analysis revealed mutation patterns of de-differentiated liposarcoma and leiomyosarcoma.
    Liu W; Tong H; Zhang C; Zhuang R; Guo H; Lv C; Yang H; Lin Q; Guo X; Wang Z; Wang Y; Shen F; Wang S; Dai C; Wang G; Liu J; Lu W; Zhang Y; Zhou Y
    BMC Cancer; 2020 Oct; 20(1):1035. PubMed ID: 33115433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developing Novel Genomic Risk Stratification Models in Soft Tissue and Uterine Leiomyosarcoma.
    Dermawan JK; Chiang S; Singer S; Jadeja B; Hensley ML; Tap WD; Movva S; Maki RG; Antonescu CR
    Clin Cancer Res; 2024 May; 30(10):2260-2271. PubMed ID: 38488807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Use of p16 in enhancing the histologic classification of uterine smooth muscle tumors.
    Atkins KA; Arronte N; Darus CJ; Rice LW
    Am J Surg Pathol; 2008 Jan; 32(1):98-102. PubMed ID: 18162776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inactivating Mutations of RB1 and TP53 Correlate With Sarcomatous Histomorphology and Metastasis/Recurrence in Gastrointestinal Stromal Tumors.
    Merten L; Agaimy A; Moskalev EA; Giedl J; Kayser C; Geddert H; Schaefer IM; Cameron S; Werner M; Ströbel P; Hartmann A; Haller F
    Am J Clin Pathol; 2016 Dec; 146(6):718-726. PubMed ID: 28028119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.